Shopping Cart
- Remove All
Your shopping cart is currently empty
ACT-1004-1239
🥰Excellent
Catalog No. T39665Cas No. 2178049-58-4
ACT-1004-1239 is an orally active, selective, and potent CXCR7 antagonist with immune-modulatory and myelin-promoting effects. It can be used to study inflammatory demyelinating diseases.
ACT-1004-1239
🥰Excellent
Purity: 98.31%
Catalog No. T39665Cas No. 2178049-58-4
ACT-1004-1239 is an orally active, selective, and potent CXCR7 antagonist with immune-modulatory and myelin-promoting effects. It can be used to study inflammatory demyelinating diseases.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $213 | In Stock | |
| 5 mg | $538 | In Stock | |
| 10 mg | $868 | In Stock | |
| 25 mg | $1,780 | In Stock | |
| 50 mg | $2,860 | In Stock |
Add to Cart
Add to Quotation
Bulk & Custom
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
View MoreBatch Information
Select Batch
Purity:98.31%
Contact us for more batch information
Product Introduction
Bioactivity
Chemical Properties
| Description | ACT-1004-1239 is an orally active, selective, and potent CXCR7 antagonist with immune-modulatory and myelin-promoting effects. It can be used to study inflammatory demyelinating diseases. |
| Targets&IC50 | CXCR7 (human):3.2 nM, CXCR7 (dog):2.3 nM |
| In vitro | ACT-1004-1239 inhibits CXCR7 in human, dog, rat, mouse, guinea pig and macaque with IC50s of 3.2, 2.3, 3.1, 2.3, 0.6 and 1.5 nM, respectively. [1] ACT-1004-1239 promotes the maturation of OPCs into myelin oligodendrocytes. [2] |
| In vivo | In a MOG-induced mouse model of EAE, ACT-1004-1239 treatment (10-100 mg/kg twice daily, orally) showed a significant dose-dependent reduction in the clinical score of the disease, leading to an increase in survival. At the highest dose tested (100 mg/kg twice daily), ACT-1004-1239 delayed disease onset and significantly reduced immune cell infiltration into the CNS and plasma filament light chain concentrations. [2] ACT-1004-1239 reduces pulmonary vascular permeability and reduces inflammatory cell infiltration. [3] |
| Molecular Weight | 522.55 |
| Formula | C27H28F2N6O3 |
| Cas No. | 2178049-58-4 |
| Smiles | N(C(=O)[C@@H]1[C@@H](NC(=O)C=2C=C(ON2)C3=C(F)C=C(F)C=C3)CCN(CC4CC4)C1)C5(CC5)C=6N=CC=CN6 |
Storage & Solubility Information
| Storage | keep away from moisture,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||
| Solubility Information | DMSO: 5.00 mg/mL (9.57 mM), Sonication is recommended. | |||||||||||||||
Solution Preparation Table | ||||||||||||||||
DMSO
| ||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% Saline/PBS/ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Sci Citations
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy ACT-1004-1239 | purchase ACT-1004-1239 | ACT-1004-1239 cost | order ACT-1004-1239 | ACT-1004-1239 chemical structure | ACT-1004-1239 in vivo | ACT-1004-1239 in vitro | ACT-1004-1239 formula | ACT-1004-1239 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.